Akiko Yoshida
Overview
Explore the profile of Akiko Yoshida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoshida A, Murakami K, Tsukamoto H, Hotta Y, Nakayama Y, Saito R, et al.
Mod Rheumatol
. 2025 Mar;
PMID: 40048675
Objectives: Polyunsaturated fatty acids (PUFAs) are healthy fats that contain a double carbon bond. They are made up of omega (ω)-3 and ω-6 PUFAs, where ω-3 PUFAs exhibit beneficial effects,...
2.
Reference-Based Standardization Approach Stabilizing Small Batch Risk Prediction via Polygenic Score
Sutoh Y, Hachiya T, Otsuka-Yamasaki Y, Tokutomi T, Yoshida A, Kotozaki Y, et al.
Genet Epidemiol
. 2025 Jan;
49(2):e70002.
PMID: 39888077
The polygenic score (PGS) holds promise for motivating preventive behavioral changes. However, no clinically validated standardization methodology currently exists. Here, we demonstrate the efficacy of a "reference-based" approach for standardization....
3.
Fukushima T, Manabe M, Yada S, Wakamiya S, Yoshida A, Urakawa Y, et al.
JMIR Med Inform
. 2025 Jan;
13:e65047.
PMID: 39819819
Background: Advances in genetics have underscored a strong association between genetic factors and health outcomes, leading to an increased demand for genetic counseling services. However, a shortage of qualified genetic...
4.
Osawa H, Matsukawa M, Yoshida A, Torishima M, Murakami H, Haruyama S, et al.
J Genet Couns
. 2024 Oct;
PMID: 39367595
Huntington's disease (HD) is a neurodegenerative disease with autosomal dominant inheritance, and no radical cure for HD has been established. Qualitative studies are necessary to investigate the psychological state of...
5.
Yoshida A, Pirabul K, Fujii S, Pan Z, Yoshii T, Ito M, et al.
ACS Appl Mater Interfaces
. 2024 Aug;
16(38):50115-50124.
PMID: 39161048
In recent years, significant attention has been directed toward advancing compact, point-of-care testing (POCT) devices to better deliver patient care and alleviate the burden on the medical care system. Common...
6.
Hiraoka M, Urakawa Y, Kawai K, Yoshida A, Hosakawa J, Takazawa M, et al.
PLoS One
. 2024 Jun;
19(6):e0305812.
PMID: 38913662
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy and a major cause of blindness. RP is caused by several variants of multiple genes, and genetic diagnosis by identifying...
7.
Tokutomi T, Yoshida A, Fukushima A, Yamamoto K, Ishigaki Y, Kawame H, et al.
Genes (Basel)
. 2024 Mar;
15(3).
PMID: 38540442
Genetic testing is key in modern healthcare, particularly for monogenic disorders such as familial hypercholesterolemia. This Tohoku Medical Megabank Project study explored the impact of first-degree relatives' dyslipidemia history on...
8.
Tokutomi T, Yoshida A, Fukushima A, Nagami F, Minoura Y, Sasaki M
Genes (Basel)
. 2024 Jan;
15(1).
PMID: 38254940
Genome-wide association studies have been employed to develop numerous risk prediction models using polygenic risk scores (PRSs) for multifactorial diseases. However, healthcare providers lack confidence in their understanding of PRS...
9.
Inatani M, Orii Y, Iwasaki K, Arimura S, Sunagawa H, Shiokawa M, et al.
Adv Ther
. 2023 Jul;
40(9):4074-4092.
PMID: 37452961
Introduction: This multicenter, randomized, comparative, and investigator-masked crossover clinical trial sought to compare the efficacy and tolerability of fixed combinations of 0.1% brimonidine/0.5% timolol (BTFC) versus 1% dorzolamide/0.5% timolol (DTFC)...
10.
Miura M, Sakaue F, Matsuno H, Morita K, Yoshida A, Hara R, et al.
FEBS Lett
. 2023 May;
597(12):1667-1676.
PMID: 37177801
Aggregation of the 43 kDa TAR DNA-binding protein (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RNA binding and TDP-43 N-terminal domain dimerisation...